Journal article
NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy
N Hardcastle, MS Hofman, CY Lee, J Callahan, L Selbie, F Foroudi, M Shaw, S Chander, A Lim, B Chesson, DG Murphy, T Kron, S Siva
Radiation Oncology | BMC | Published : 2019
Abstract
Introduction: In prostate cancer patients, imaging of bone metastases is enhanced through the use of sodium fluoride positron emission tomography (18F-NaF PET/CT). This imaging technique shows areas of enhanced osteoblastic activity and blood flow. In this work, 18F-NaF PET/CT was investigated for response assessment to single fraction stereotactic ablative body radiotherapy (SABR) to bone metastases in prostate cancer patients. Methods: Patients with bone metastases in a prospective trial treated with single fraction SABR received a 18F-NaF PET/CT scan prior to and 6 months post-SABR. The SUVmax in the tumour was determined and the difference between before and after SABR determined. The ch..
View full abstractGrants
Funding Acknowledgements
The Prostate Cancer Foundation of Australia and the Movember Foundation provided funding for the study. MSH and SS are supported by Clinical Fellowship Awards from the Peter MacCallum Foundation.